Ovarian carcinoma cells effectively inhibit differentiation and maturation of dendritic cells derived from hematopoietic progenitor cells in vitro

Cancer Investigation

Volumn 23, Issue 5, 2005, Pages 379-385

  Ye, Feng ^a   Chen, Huai Zeng ^a   Xie, Xing ^a   Ye, Da Feng ^a   Lu, Wei Guo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

CD34+ hemopoietic progenitor cells; Dendritic cells; Ovarian carcinoma; Vascular endothelial growth factor

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 12; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL CORD BLOOD;

ANTIBODIES; ANTIGENS, CD34; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24944592390     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-67128     Document Type: Article

References (33)

1. Melichar, B.; Nash, M.A.; Lenzi, R.; Platsoucas, C.D.; Freedman, R.S. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin. Exp. Immunol. 2000, 119, 19-27.
2. Loercher, A.E.; Nash, M.A.; Kavanagh, J.J.; Platsoucas, C.D.; Freedman, R.S. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. 1999, 163, 6251-6260.
3. Berek, J.S.; Bast, R.C., Jr.; Lichtenstein, A.; Hacker, N.F.; Spina, C.A.; et al. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet. Gynecol. 1984, 64, 708-714.
4. Chen, C.K.; Wu, M.Y.; Chao, K.H.; Ho, H.N.; Sheu, B.C.; Huang, S.C. T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies. J. Formes. Med. Assoc. 1999, 98, 24-30.
5. Markowska, J.; Lachi, J.K.; Jaroszewski, J.; Wiktorowicz, K. The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients. Eur. J. Gynaecol. Oncol. 1995, 16, 54-58.
6. Richters, C.D.; Burger, C.W.; van de Loosdrecht, A.A.; van Rijswijk, R.E.; Calame, W.; et al. The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment. Cancer Lett. 1993, 68, 25-31.
7. Eisenthal, A.; Polyvkin, N.; Bramante-Schreiber, L.; Misonznik, F.; Hassner, A.; Lifschitz-Mercer, B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Human Pathol. 2001, 32, 803-807.
8. Iwamoto, M.; Shinohara, H.; Miyamoto, A.; Okuzawa, M.; et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 2003, 104, 92-97.
9. Inoue, K.; Yamashita, A.; Yamashita, M.; Morioka, M.; Fujita, Y.; Terao, N. Distribution of S-IOO protein-positive dendritic cells inside the cancer nest and expression of HLA-DR antigen and blood group antigen on the cancer cell in transitional cell carcinoma of the urinary bladder-in relation to tumor progression and prognosis. Nippon Hinyokika Gakkai Zasshi 1994, 85, 495-503.
10. Zavadova, E.; Savary, C.A.; Templin, S.; Verschraegen, C.F.; Freedman, R.S. Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother. Pharmacol. 2001, 48, 289-296.
11. Melichar, B.; Savary, C.; Kudelka, A.P.; Verschraegen, C.; Kavanagh, J.J.; et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin. Cancer Res. 1998, 4, 799-809.
12. Santin, A.D.; Bellone, S.; Ravaggi, A.; Roman, J.; Smith, C.V.; Pecorelli, S.; Cannon, MJ.; Parham, G.P. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001, 108, 804-808.
13. Kryczek, I.; Grybos, M.; Karabon, L.; Klimczak, A.; Lange, A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br. J. Cancer 2000, 82, 621-628.
14. Fujita, T.; Miyamoto, S.; Onoyama, I.; Sonoda, K.; Mekada, E.; Nakano, H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003, 192, 161-169.
15. Yabushita, H.; Shimazu, M.; Noguchi; Kishida, T.; Narumiya, H.; Sawaguchi, K.; Noguchi, M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol. Rep. 2003, 10, 89-95.
16. Santin, A.D.; Hermonat, P.L.; Ravagge, A.; Cannon, M.J.; Pecorelli, S.; Parham, G.P. Secretion of vascular endothelial growth factor in ovarian cancer. Eur. J. Gynaecol. Oncol. 1999, 20, 177-181.
17. Molica, S.; Vacca, A.; Ribatti, D.; Cuneo, A.; Cavazzini, F.; et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002, 100, 3344-3351.
18. Candido Dos Reis, F.J.; Moreira de Andrade, J.; Bighetti, S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol. Obstet. Invest. 2002, 54, 132-136.
19. Kaneko, T.; Konno, H.; Baba, M.; Tanaka, T.; Nakamura, S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci. 2003, 94, 43-49.
20. Alexandrakis, M.G.; Passam, F.H.; Boula, A.; Christophoridou, A.; Aloizos, G.; Roussou, P.; Kyriakou, D.S. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann. Hematol. 2003, 82, 19-23.
21. Manders, P.; Beex, L.V.; Tjan-Heijnen, V.C.; Geurts-Moespot, J.; Van Tienoven, T.H.; Foekens, J.A.; Sweep, C.G. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br. J. Cancer 2002, 87, 772-778.
22. Ohm, J.E.; Carbone, D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 2001, 23, 263-272.
23. Young, M.R.; Petruzzelli, G.J.; Kolesiak, K.; Achille, N.; Lathers, D.M.; Gabrilovich, D.I. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34 (+) progenitor cells. Hum. Immunol. 2001, 62, 332-341.
24. Oyama, T.; Ran, S.; Ishida, T.; Nadaf, S.; Kerr, L.; Carbone, D.P.; Gabrilovich, D.I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 1998, 160, 1224-1232.
25. Ohm, J.E.; Gabrilovich, D.I.; Sempowski, G.D.; Kisseleva, E.; Parman, K. S.; Nadaf, S.; Carbone, D.P. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101, 4878-4886.
26. Inoshima, N.; Nakanishi, Y.; Minami, T.; Izumi, M.; Takayama, K.; Yoshino, I.; Hara, N. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin. Cancer Res. 2002, 8, 3480-3486.
27. Takahashi, A.; Kono, K.; Itakura, J.; Amemiya, H.; Feng Tang, R.; et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002, 62, 121-127.
28. Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D.P. Vascular endothelial growth factor inhibits the demelopment of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92, 4150-4166.
29. Hamai, J.; Yakushiji, M.; Miyahara, K.; Okura, N.; Tazaki, T.; Nishimura, H.; Kato, T. Studies of immunological function in patients with ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1985, 37, 1875-1882.
30. Zou, W.; Machelon, V.; Coulomb-L'Hermin, A.; Borvak, J.; Nome, F.; et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7, 1339-1346.
31. Yang, A.S.; Lattime, E.G. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 2003, 63, 2150-2157.
32. Buelens, C.; Verhasselt, V.; De Groote, D.; Thielemans, K.; Goldman, M.; Willems, F. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur. J. Immunol. 1997, 27, 756-762.
33. Menetrier-Caux, C.; Montmain, G.; Dieu, M.C.; Bain, C.; et al. Inhibition of the differentiation of dendritic cells from CD34 (+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 92, 4778-4791.